Treatment of panic disorder: Recent developments and current status

Expert Review of Neurotherapeutics

Volumn 8, Issue 8, 2008, Pages 1219-1232

  Starcevic, Vladan ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Agoraphobia; Benzodiazepines; Cognitive therapy; Cognitive behavior therapy; Combined treatment; Exposure based treatments; Panic disorder; Pharmacological treatment; Selective serotonin reuptake inhibitors

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOMIPRAMINE; CLONAZEPAM; CYCLOSERINE; GABAPENTIN; IMIPRAMINE; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENELZINE; PLACEBO; PREGABALIN; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; VIGABATRIN;

AGITATION; AGORAPHOBIA; ANTICHOLINERGIC EFFECT; ANXIETY; CLINICAL TRIAL; COGNITIVE THERAPY; COPING BEHAVIOR; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; EXERCISE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PANIC; PSYCHODYNAMICS; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; RECURRENT DISEASE; RESTLESSNESS; REVIEW; RISK REDUCTION; SEDATION; SELF CONCEPT; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; TREATMENT INDICATION; TREATMENT REFUSAL; TREATMENT RESPONSE; VIRTUAL REALITY; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; HUMANS; PANIC DISORDER; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTHERAPY; RECURRENCE;

EID: 49449099565     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.8.1219     Document Type: Review

References (98)

1. Wittchen H-U, Nocon A, Beesdo K et al. Agoraphobia and panic: prospective-longitudinal relations suggest a rethinking of diagnostic concepts. Psychother. Psychosom. 77, 147-157 (2008).
2. Faravelli C, Cosci F, Rotella F, Faravelli L, Dell'Osso MC. Agoraphobia between panic and phobias: clinical epidemiology from the Sesto Fiorentino Study. Compr. Psychiatry 49, 283-287 (2008).
3. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 63, 415-424 (2006).
4. Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J. Clin. Psychiatry 57(Suppl. 10), 11-22 (1996).
5. Tyrer P, Seivewright H Johnson T. The Nottingham study of neurotic disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol. Med. 34, 1385-1394 (2004).
6. Sareen J, Cox BJ, Afifi TO et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch. Gen. Psychiatry 62, 1249-1257 (2005).
7. Smoller JW, Pollack MH, Wassertheil-Smoller S et al. Panic attacks and risk of incident cardiovascular vents among postmenopausal women in the Women's Health Initiative observational Study. Arch. Gen. Psychiatry 64, 1153-1160 (2007).
8. Stein MB, Sherbourne CD, Craske MG et al. Quality of care for primary care patients with anxiety disorders. Am. J. Psychiatry 161, 2230-2237 (2004).
9. Nadiga DN, Hensley PL, Uhlenhuth EH. Review of the long-term effectiveness of cognitive behavioral therapy compared to medications in panic disorder. Depress. Anxiety 17, 58-64 (2003).
10. Fava GA, Rafanelli C, Grandi S et al. Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol. Med. 31, 891-898 (2001).
11. Rapaport MH, Pollack MH, Clary CM, Mardekian J, Wolkow R. Panic disorder and response to sertraline: the effect of previous treatment with benzodiazepines. J. Clin. Psychopharmacol. 21, 104-107 (2001).
12. Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J. Clin. Psychopharmacol. 22, 294-299 (2002).
13. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J. Affect. Disord. 88, 27-45 (2005). •• Very ambitious study, successfully integrating a large amount of data about the efficacy of all relevant treatments for panic disorder. It compared not only cognitive-behavior therapy to pharmacotherapy, but also included combinations of these main treatment modalities and comparisons between various forms of cognitive-behavior therapy and various types of medications.
14. Dusseldorp E, Spinhoven P, Bakker A, van Dyck R, van Balkom AJLM. Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants? Psychother. Psychosom. 76, 154-161 (2007). • Example of the urgently needed type of studies, looking at the match between certain personality characteristics of patients with panic disorder and outcome of different types of treatment. Such studies could help in choosing appropriate treatment for various patients with panic disorder.
15. Shear MK, Brown TA, Barlow DH et al. Multicenter collaborative Panic Disorder Severity Scale. Am. J. Psychiatry 154, 1571-1575 (1997).
16. Bandelow B. Assessing the efficacy of treatment for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int. Clin. Psychopharmacol. 10, 73-81 (1995).
17. Öst L-G, Thulin U, Ramnerö J. Cognitive behavior therapy vs. exposure in vivo in the treatment of panic disorder with agoraphobia. Behav. Res. Ther. 42, 1105-1127 (2004).
18. Salkovskis PM, Hackmann A, Wells A, Gelder MG, Clark DM. Belief disconfirmation versus habituation approaches to situational exposure in panic disorder with agoraphobia: a pilot study. Behav. Res. Ther. 44, 877-885 (2006).
19. Norton PJ, Price EC. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J. Nerv. Ment. Dis. 195, 521-531 (2007).
20. Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J. Clin. Psychiatry 69, 621-632 (2008).
21. Smits JAJ, Powers MB, Cho Y, Telch MJ. Mechanism of change in cognitive-behavioral treatment of panic disorder: evidence for the fear of fear mediational hypothesis. J. Consult. Clin. Psychol. 72, 646-652 (2004).
22. Hofmann SG, Meuret AE, Rosenfield D et al. Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorder. J. Consult. Clin. Psychol. 75, 374-379 (2007).
23. Bouchard S, Gauthier J, Nouwen A et al. Temporal relationship between dysfunctional beliefs, self-efficacy and panic apprehension in the treatment of panic disorder with agoraphobia. J. Behav. Ther. Exp. Psychiatry 38, 275-292 (2007).
24. Hofmann SG. Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders. Clin. Psychol. Rev. 28, 200-211 (2008). •• Important overview of the cognitive processes involved in the etiology of anxiety disorders and their treatment by means of exposure-based therapy. Integrates findings from research on animals and humans and considers the putative neurobiological underpinnings of the cognitive processes in the anxiety disorders.
25. Longmore RJ, Worrell M. Do we need to challenge thoughts in cognitive behavior therapy? Clin. Psychol. Rev. 27, 173-187 (2007).
26. Johansson P, Høglend P. Identifying mechanisms of change in psychotherapy: mediators of treatment outcome. Clin. Psychol. Psychother. 14, 1-9 (2007).
27. Addis ME, Hatgis C, Krasnow AD, Jacob K, Bourne L, Mansfield A. Effectiveness of cognitive-behavioral treatment for panic disorder versus treatment as usual in a managed care setting. J. Consult. Clin. Psychol. 72, 625-635 (2004).
28. Addis ME, Hatgis C, Cardemil E, Jacob K, Krasnow AD, Mansfield A. Effectiveness of cognitive-behavioral treatment for panic disorder versus treatment as usual in a managed care setting: 2-year follow-up. J. Consult. Clin. Psychol. 74, 377-385 (2006).
29. Roy-Byrne PP, Katon W, Cowley DS, Russo J. A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care. Arch. Gen. Psychiatry 58, 869-876 (2001).
30. Roy-Byrne PP, Craske MG, Stein MB et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch. Gen. Psychiatry 62, 290-298 (2005).
31. Rollman BL, Belnap BH, Mazumdar S et al. A randomized trial to improve the quality of treatment for panic and generalized anxiety disorders in primary care. Arch. Gen. Psychiatry 62, 1332-1341 (2005).
32. van Apeldoorn FJ, van Hout WJPJ, Mersch PPA et al. Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr. Scand. 117, 260-270 (2008).
33. Dow MGT, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A. Prognostic indices with brief and standard CBT for panic disorder: II. Moderators of outcome. Psychol. Med. 37, 1503-1509 (2007).
34. Deacon B, Abramowitz J. A pilot study of two-day cognitive-behavioral therapy for panic disorder. Behav. Res. Ther. 44, 807-817 (2006).
35. Lamplugh C, Berle D, Milicevic D, Starcevic V. A pilot study of cognitive-behaviour therapy for panic disorder augmented by panic surfing. Clin. Psychol. Psychother. (in press).
36. Morissette SB, Spiegel DA, Heinrichs N. Sensation-focused intensive treatment for panic disorder with moderate to severe agoraphobia. Cogn. Behav. Practice 12, 17-29 (2005).
37. Bitran S, Morissette SB, Spiegel DA, Barlow DH. A pilot study of sensation-focused intensive treatment for panic disorder with moderate to severe agoraphobia: preliminary outcome and benchmarking data. Behav. Modif. 32, 196-214 (2008).
38. Sharp DM, Power KG, Swanson V. A comparison of the efficacy and acceptability of group versus individual cognitive behaviour therapy in the treatment of panic disorder and agoraphobia in primary care. Clin. Psychol. Psychother. 11, 73-82 (2004).
39. Marks IM, Kenwright M, McDonough M, Whittaker M, Mataix-Cols D. Saving clinicians' time by delegating routine aspects of therapy to a computer: a randomized controlled trial in phobia/panic disorder. Psychol. Med. 34, 9-18 (2004).
40. Carlbring P, Bohman S, Brunt S et al. Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone calls. Am. J. Psychiatry 163, 2119-2125 (2006). • Well-designed study with innovative elements, describing and examining efficacy of the state-of-the-art internet-based cognitive-behavior therapy for panic disorder and pointing to its future developments.
41. Klein B, Richards JC, Austin DW. Efficacy of internet therapy for panic disorder. J. Behav. Ther. Exp. Psychiatry 37, 213-238 (2006).
42. Villa Martin H, Botella C, Garcia-Palacios A, Osma J. Virtual reality exposure in the treatment of panic disorder with agoraphobia: a case study. Cogn. Behav. Practice 14, 58-69 (2007).
43. Botella C, Garcia-Palacios A, Villa H et al. Virtual reality exposure in the treatment of panic disorder and agoraphobia: a controlled study. Clin. Psychol. Psychother. 14, 164-175 (2007).
44. Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. J. Clin. Psychiatry 58, 555-561 (1997).
45. Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch. Gen. Psychiatry 50, 51-60 (1993).
46. Bakker A, van Balkom AJLM, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr. Scand. 106, 163-167 (2002).
47. Otto MW, Tuby KS, Gould RA, McLean RS, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am. J. Psychiatry 158, 1989-1992 (2001).
48. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am. J. Psychiatry 155, 36-42 (1998).
49. Londborg PD, Wolkow R, Smith WT. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br. J. Psychiatry 173, 54-60 (1998).
50. Bandelow B, Behnke K, Lenoir S et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J. Clin. Psychiatry 65, 405-413 (2004).
51. Mavissakalian M, Perel JM. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am. J. Psychiatry 152, 673-682 (1995).
52. Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. J. Clin. Psychopharmacol. 17, 390-400 (1997).
53. Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. Arch. Gen. Psychiatry 46, 993-999 (1989).
54. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J. Clin. Psychopharmacol. 13, 257-263 (1993).
55. Worthington JJ, Pollack MH, Otto MW, McLean RYS, Moroz G, Rosenbaum JF. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol. Bull. 34, 199-205 (1998).
56. Salzman C, Miyawaki EK, le Bars P, Kerrihard TN. Neurobiologic basis of anxiety and its treatment. Harv. Rev. Psychiatry 1, 197-206 (1993).
57. Pollack MH, Lepola U, Koponen H et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress. Anxiety 24, 1-14 (2007).
58. Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J. Clin. Psychiatry 68, 58-68 (2007).
59. Woods SW, Nagy LM, Koleszar AS, Krystal JH, Heninger GR, Charney DS. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J. Clin. Psychopharmacol. 12, 32-38 (1992).
60. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney S. Early coadministration of clonazepam with sertraline for panic disorder. Arch. Gen. Psychiatry 58, 681-686 (2001).
61. Pollack MH, Simon NM, Worthington JJ et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J. Psychopharmacol. 17, 276-282 (2003).
62. Fava GA, Bernardi M, Tomba E, Rafanelli C. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int. J. Neuropsychopharmacol. 10, 835-838 (2007).
63. Mavissakalian M, Perel JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am. J. Psychiatry 149, 1053-1057 (1992).
64. Choy Y, Peselow ED, Case BG et al. Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study. Compr. Psychiatry 48, 419-425 (2007). • Although discouraging, findings of this study are most relevant for clinical practice. They call for more studies of long-term treatment of panic disorders and suggest the value of combining medications with cognitive-behavior therapy.
65. Blaya C, Seganfredo AC, Dornelles M et al. The efficacy of milnacipran in panic disorder: an open trial. Int. Clin. Psychopharmacol. 22, 153-158 (2007).
66. Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J. Clin. Psychiatry 67, 1573-1576 (2006).
67. Pande AC, Pollack MH, Crockatt J et al. Placebo-controlled study of gabapentin treatment of panic disorder. J. Clin. Psychopharmacol. 20, 467-471 (2000).
68. Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress. Anxiety 21, 33-40 (2005).
69. Sepede G, De Berardis D, Gambi F et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J. Clin. Psychopharmacol. 26, 45-49 (2006).
70. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br. J. Psychiatry 188, 305-312 (2006). •• Represents an important contribution to an understanding of how the combined (antidepressant plus cognitive-behavior therapy) treatment for panic disorder compares with treatments with antidepressants alone and cognitive-behavior therapy alone. Illuminates this controversial area in a scientifically rigorous and well-balanced manner.
71. Watanabe N, Churchill R, Furukawa TA. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry 7, 18 (2007).
72. McHugh RK, Otto MW, Barlow DH, Gorman JM, Shear MK, Woods SW. Cost-efficacy of individual and combined treatments for panic disorder. J. Clin. Psychiatry 68, 1038-1044 (2007).
73. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 283, 2529-2536 (2000).
74. Craske MG, Golinelli D, Stein MB, Roy-Byrne P, Bystritsky A, Sherbourne C. Does the addition of cognitive-behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting? Psychol. Med. 35, 1645-1654 (2005).
75. Marks IM, Swinson RP, Basoglu M et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br. J. Psychiatry 162, 776-787 (1993).
76. Wardle J, Hayward P, Higgitt A, Stabl M, Blizard R, Gray J. Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia. Behav. Res. Ther. 32, 203-215 (1994).
77. Basoglu M, Marks IM, Kilic C, Brewin CR, Swinson RP. Alprazolam and exposure for panic disorder with agoraphobia: attribution of improvement to medication predicts subsequent relapse. Br. J. Psychiatry 164, 652-659 (1994).
78. Starcevic V, Linden M, Uhlenhuth EH, Kolar D, Latas M. Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: factors influencing psychiatrists' treatment choices. Psychiatry Res. 125, 41-52 (2004).
79. Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch. Gen. Psychiatry 53, 689-694 (1996).
80. Arch JJ, Craske MG. Implications of naturalistic use of pharmacotherapy in CBT treatment for panic disorder. Behav. Res. Ther. 45, 1435-1447 (2007).
81. Mavissakalian MR, Guo S. Early detection of relapse in panic disorder. Acta Psychiatr. Scand. 110, 393-399 (2004).
82. Ressler KJ, Rothbaum BO, Tannenbaum L et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 61, 1136-1144 (2004).
83. Hofmann SG, Meuret AE, Smits JAJ et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry 63, 298-304 (2006).
84. Guastella AJ, Richardson R, Lovibond PF et al. A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol. Psychiatry 63, 544-549 (2008).
85. Wilhelm S, Buhlmann U, Tolin DF et al. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am. J. Psychiatry 165, 335-341 (2008).
86. Tolin DF, Pearlson GD, Krystal JH et al. A controlled trial of d-cycloserine with brief CBT for panic disorder. Presented at: The 40th Annual Convention of the Association for Behavioral and Cognitive Therapies, Chicago (2006).
87. Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn. Mem. 11, 510-516 (2004).
88. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J. Psychiatr. Res. 41, 466-471 (2007).
89. Storch EA, Merlo LJ, Bengtson M et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 22, 230-237 (2007).
90. Milrod BL, Busch FN, Cooper AM, Shapiro T. Manual of Panic-Focused Psychodynamic Psychotherapy. American Psychiatric Press, Washington, DC, USA (1997).
91. Milrod B, Busch F, Leon AC et al. Open trial of psychodynamic psychotherapy for panic disorder: a pilot study. Am. J. Psychiatry 157, 1878-1880 (2000).
92. Milrod B, Busch F, Leon AC et al. A pilot open trial of brief psychodynamic psychotherapy for panic disorder. J. Psychother. Pract. Res. 10, 239-245 (2001).
93. Milrod B, Leon AC, Busch F et al. A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder. Am. J. Psychiatry 164, 265-272 (2007).
94. Milrod BL, Leon AC, Barber JP, Markowitz JC, Graf E. Do comorbid personality disorders moderate panic-focused psychotherapy? An exploratory examination of the American Psychiatric Association Practice Guidelines. J. Clin. Psychiatry 68, 885-891 (2007).
95. Lipsitz JD, Gur M, Miller NL, Forand N, Vermes D, Fyer AJ. An open pilot study of interpersonal psychotherapy for panic disorder (IPT-PD). J. Nerv. Ment. Dis. 194, 440-445 (2006).
96. Ströhle A, Feller C, Onken M, Godemann F, Heinz A, Dimeo F. The acute antipanic activity of aerobic exercise. Am. J. Psychiatry 162, 2376-2378 (2005).
97. Broocks A, Bandelow B, Pekrun G et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am. J. Psychiatry 155, 603-609 (1998).
98. Smits JAJ, Powers MB, Berry AC, Otto MW. Translating empirically supported strategies into accessible interventions: the potential utility of exercise for the treatment of panic disorder. Cogn. Behav. Practice 14, 364-374 (2007).